Global Bioidentical Hormones Market

Bioidentical Hormones Comprehensive Study by Type (Estrogens, Progesterone, Testosterone, Others), Product (Tablets and Capsules, Creams and Gels, Injectable, Patches and Implants, Others), End User (Hospitals & Gynecology Clinics, Academic and Research, Others) Players and Region - Global Market Outlook to 2029

Bioidentical Hormones Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Bioidentical Hormones Market Scope
Bioidentical hormones are man-made hormones that resemble the same chemical and molecular structure as natural hormones produced endogenously in a human body. Bioidentical hormones include estrogen (estradiol, estriol, and estrone), progesterone, testosterone, and dehydroepiandrosterone (DHEA). The global bioidentical hormones market is expected to rise in the future due to rising research ad development activities and rising hormonal imbalance cases.

AttributesDetails
Study Period2019-2029
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledBiote Medical (United States), Sottopell (United States), Novartis AG (Switzerland), Full Life Wellness Center (United States), Advantage Pharmaceuticals, inc (United States), Pfizer Inc (United States), Defy medical (United States), GeneScience Pharmaceuticals Co., Ltd (China) and Neuva aesthetics (United States)
CAGR%


The top firms are in a competition that has their strong R&D backup for research studies and the further things which are required to get approval for such complicated drugs and enhance the treatment medications. There are firms mainly from the USA and playing a major role in the research area of Bioidentical Hormones. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Bioidentical Hormones market throughout the predicted period.

Biote Medical (United States), Sottopell (United States), Novartis AG (Switzerland), Full Life Wellness Center (United States), Advantage Pharmaceuticals, inc (United States), Pfizer Inc (United States), Defy medical (United States), GeneScience Pharmaceuticals Co., Ltd (China) and Neuva aesthetics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Bioidentical Hormone Clinic (Australia), Pharmac Biopharma (United Kingdom), Biosyn Arzneimittel GmbH (Germany) and Bioidentical Hormone Clinic (Australia).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Bioidentical Hormones market by Type and Region with country level break-up.

On the basis of geography, the market of Bioidentical Hormones has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In October 2023, Emerson Therapeutics, Inc., a prominent player in bioidentical hormone replacement therapy (BHRT), acquired Harmony Health, a California-based clinic specializing in personalized hormone therapy. This acquisition expands Emerson's reach and strengthens its presence in the western United States.
In December 2023, The Woodlands Wellness Centre introduced its personalized bioidentical hormone cream formulations, tailored to individual patients' hormone profiles and addressing specific health concerns. This personalized approach reflects the growing trend towards precision medicine in hormone therapy.


Influencing Trend:
Growing Screening for Hormonal Deficiency

Market Growth Drivers:
Rising Prevalence of Hormonal Imbalance Disorders and Increasing Focus on Women Health Care & Treatment of Hormonal among Women

Challenges:
Lack of Awareness among the Population and Low Healthcare Expenditure in Several Region

Restraints:
Safety Issues related to the Use of Compound Bioidentical Hormones

Opportunities:
Rising Research and Development Activities in Developing Countries and Growth in the Health Care Industry

Key Target Audience
Global Bioidentical Hormones treatment manufacturers & suppliers, Research and development (R&D) companies, Hospitals and clinics and Academic institutes and universities

Report Objectives / Segmentation Covered

By Type
  • Estrogens
  • Progesterone
  • Testosterone
  • Others
By Product
  • Tablets and Capsules
  • Creams and Gels
  • Injectable
  • Patches and Implants
  • Others

By End User
  • Hospitals & Gynecology Clinics
  • Academic and Research
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Prevalence of Hormonal Imbalance Disorders
      • 3.2.2. Increasing Focus on Women Health Care & Treatment of Hormonal among Women
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness among the Population
      • 3.3.2. Low Healthcare Expenditure in Several Region
    • 3.4. Market Trends
      • 3.4.1. Growing Screening for Hormonal Deficiency
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Bioidentical Hormones, by Type, Product, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Bioidentical Hormones (Value)
      • 5.2.1. Global Bioidentical Hormones by: Type (Value)
        • 5.2.1.1. Estrogens
        • 5.2.1.2. Progesterone
        • 5.2.1.3. Testosterone
        • 5.2.1.4. Others
      • 5.2.2. Global Bioidentical Hormones by: Product (Value)
        • 5.2.2.1. Tablets and Capsules
        • 5.2.2.2. Creams and Gels
        • 5.2.2.3. Injectable
        • 5.2.2.4. Patches and Implants
        • 5.2.2.5. Others
      • 5.2.3. Global Bioidentical Hormones by: End User (Value)
        • 5.2.3.1. Hospitals & Gynecology Clinics
        • 5.2.3.2. Academic and Research
        • 5.2.3.3. Others
      • 5.2.4. Global Bioidentical Hormones Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Bioidentical Hormones: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biote Medical (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sottopell (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Full Life Wellness Center (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Advantage Pharmaceuticals, inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Defy medical (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GeneScience Pharmaceuticals Co., Ltd (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Neuva aesthetics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Bioidentical Hormones Sale, by Type, Product, End User and Region (value) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Bioidentical Hormones (Value)
      • 7.2.1. Global Bioidentical Hormones by: Type (Value)
        • 7.2.1.1. Estrogens
        • 7.2.1.2. Progesterone
        • 7.2.1.3. Testosterone
        • 7.2.1.4. Others
      • 7.2.2. Global Bioidentical Hormones by: Product (Value)
        • 7.2.2.1. Tablets and Capsules
        • 7.2.2.2. Creams and Gels
        • 7.2.2.3. Injectable
        • 7.2.2.4. Patches and Implants
        • 7.2.2.5. Others
      • 7.2.3. Global Bioidentical Hormones by: End User (Value)
        • 7.2.3.1. Hospitals & Gynecology Clinics
        • 7.2.3.2. Academic and Research
        • 7.2.3.3. Others
      • 7.2.4. Global Bioidentical Hormones Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Bioidentical Hormones: by Type(USD Million)
  • Table 2. Bioidentical Hormones Estrogens , by Region USD Million (2018-2023)
  • Table 3. Bioidentical Hormones Progesterone , by Region USD Million (2018-2023)
  • Table 4. Bioidentical Hormones Testosterone , by Region USD Million (2018-2023)
  • Table 5. Bioidentical Hormones Others , by Region USD Million (2018-2023)
  • Table 6. Bioidentical Hormones: by Product(USD Million)
  • Table 7. Bioidentical Hormones Tablets and Capsules , by Region USD Million (2018-2023)
  • Table 8. Bioidentical Hormones Creams and Gels , by Region USD Million (2018-2023)
  • Table 9. Bioidentical Hormones Injectable , by Region USD Million (2018-2023)
  • Table 10. Bioidentical Hormones Patches and Implants , by Region USD Million (2018-2023)
  • Table 11. Bioidentical Hormones Others , by Region USD Million (2018-2023)
  • Table 12. Bioidentical Hormones: by End User(USD Million)
  • Table 13. Bioidentical Hormones Hospitals & Gynecology Clinics , by Region USD Million (2018-2023)
  • Table 14. Bioidentical Hormones Academic and Research , by Region USD Million (2018-2023)
  • Table 15. Bioidentical Hormones Others , by Region USD Million (2018-2023)
  • Table 16. South America Bioidentical Hormones, by Country USD Million (2018-2023)
  • Table 17. South America Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 18. South America Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 19. South America Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 20. Brazil Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 21. Brazil Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 22. Brazil Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 23. Argentina Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 24. Argentina Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 25. Argentina Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 26. Rest of South America Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 28. Rest of South America Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 29. Asia Pacific Bioidentical Hormones, by Country USD Million (2018-2023)
  • Table 30. Asia Pacific Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 31. Asia Pacific Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 32. Asia Pacific Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 33. China Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 34. China Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 35. China Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 36. Japan Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 37. Japan Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 38. Japan Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 39. India Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 40. India Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 41. India Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 42. South Korea Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 43. South Korea Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 44. South Korea Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 45. Taiwan Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 46. Taiwan Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 47. Taiwan Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 48. Australia Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 49. Australia Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 50. Australia Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 54. Europe Bioidentical Hormones, by Country USD Million (2018-2023)
  • Table 55. Europe Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 56. Europe Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 57. Europe Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 58. Germany Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 59. Germany Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 60. Germany Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 61. France Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 62. France Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 63. France Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 64. Italy Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 65. Italy Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 66. Italy Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 67. United Kingdom Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 68. United Kingdom Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 69. United Kingdom Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 70. Netherlands Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 71. Netherlands Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 72. Netherlands Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 73. Rest of Europe Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 74. Rest of Europe Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 75. Rest of Europe Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 76. MEA Bioidentical Hormones, by Country USD Million (2018-2023)
  • Table 77. MEA Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 78. MEA Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 79. MEA Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 80. Middle East Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 81. Middle East Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 82. Middle East Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 83. Africa Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 84. Africa Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 85. Africa Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 86. North America Bioidentical Hormones, by Country USD Million (2018-2023)
  • Table 87. North America Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 88. North America Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 89. North America Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 90. United States Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 91. United States Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 92. United States Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 93. Canada Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 94. Canada Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 95. Canada Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 96. Mexico Bioidentical Hormones, by Type USD Million (2018-2023)
  • Table 97. Mexico Bioidentical Hormones, by Product USD Million (2018-2023)
  • Table 98. Mexico Bioidentical Hormones, by End User USD Million (2018-2023)
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Bioidentical Hormones: by Type(USD Million)
  • Table 109. Bioidentical Hormones Estrogens , by Region USD Million (2024-2029)
  • Table 110. Bioidentical Hormones Progesterone , by Region USD Million (2024-2029)
  • Table 111. Bioidentical Hormones Testosterone , by Region USD Million (2024-2029)
  • Table 112. Bioidentical Hormones Others , by Region USD Million (2024-2029)
  • Table 113. Bioidentical Hormones: by Product(USD Million)
  • Table 114. Bioidentical Hormones Tablets and Capsules , by Region USD Million (2024-2029)
  • Table 115. Bioidentical Hormones Creams and Gels , by Region USD Million (2024-2029)
  • Table 116. Bioidentical Hormones Injectable , by Region USD Million (2024-2029)
  • Table 117. Bioidentical Hormones Patches and Implants , by Region USD Million (2024-2029)
  • Table 118. Bioidentical Hormones Others , by Region USD Million (2024-2029)
  • Table 119. Bioidentical Hormones: by End User(USD Million)
  • Table 120. Bioidentical Hormones Hospitals & Gynecology Clinics , by Region USD Million (2024-2029)
  • Table 121. Bioidentical Hormones Academic and Research , by Region USD Million (2024-2029)
  • Table 122. Bioidentical Hormones Others , by Region USD Million (2024-2029)
  • Table 123. South America Bioidentical Hormones, by Country USD Million (2024-2029)
  • Table 124. South America Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 125. South America Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 126. South America Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 127. Brazil Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 128. Brazil Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 129. Brazil Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 130. Argentina Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 131. Argentina Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 132. Argentina Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 133. Rest of South America Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 134. Rest of South America Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 135. Rest of South America Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 136. Asia Pacific Bioidentical Hormones, by Country USD Million (2024-2029)
  • Table 137. Asia Pacific Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 138. Asia Pacific Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 139. Asia Pacific Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 140. China Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 141. China Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 142. China Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 143. Japan Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 144. Japan Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 145. Japan Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 146. India Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 147. India Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 148. India Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 149. South Korea Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 150. South Korea Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 151. South Korea Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 152. Taiwan Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 153. Taiwan Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 154. Taiwan Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 155. Australia Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 156. Australia Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 157. Australia Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 158. Rest of Asia-Pacific Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 159. Rest of Asia-Pacific Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 160. Rest of Asia-Pacific Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 161. Europe Bioidentical Hormones, by Country USD Million (2024-2029)
  • Table 162. Europe Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 163. Europe Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 164. Europe Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 165. Germany Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 166. Germany Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 167. Germany Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 168. France Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 169. France Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 170. France Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 171. Italy Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 172. Italy Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 173. Italy Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 174. United Kingdom Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 175. United Kingdom Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 176. United Kingdom Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 177. Netherlands Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 178. Netherlands Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 179. Netherlands Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 180. Rest of Europe Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 181. Rest of Europe Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 182. Rest of Europe Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 183. MEA Bioidentical Hormones, by Country USD Million (2024-2029)
  • Table 184. MEA Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 185. MEA Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 186. MEA Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 187. Middle East Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 188. Middle East Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 189. Middle East Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 190. Africa Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 191. Africa Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 192. Africa Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 193. North America Bioidentical Hormones, by Country USD Million (2024-2029)
  • Table 194. North America Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 195. North America Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 196. North America Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 197. United States Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 198. United States Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 199. United States Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 200. Canada Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 201. Canada Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 202. Canada Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 203. Mexico Bioidentical Hormones, by Type USD Million (2024-2029)
  • Table 204. Mexico Bioidentical Hormones, by Product USD Million (2024-2029)
  • Table 205. Mexico Bioidentical Hormones, by End User USD Million (2024-2029)
  • Table 206. Research Programs/Design for This Report
  • Table 207. Key Data Information from Secondary Sources
  • Table 208. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Bioidentical Hormones: by Type USD Million (2018-2023)
  • Figure 5. Global Bioidentical Hormones: by Product USD Million (2018-2023)
  • Figure 6. Global Bioidentical Hormones: by End User USD Million (2018-2023)
  • Figure 7. South America Bioidentical Hormones Share (%), by Country
  • Figure 8. Asia Pacific Bioidentical Hormones Share (%), by Country
  • Figure 9. Europe Bioidentical Hormones Share (%), by Country
  • Figure 10. MEA Bioidentical Hormones Share (%), by Country
  • Figure 11. North America Bioidentical Hormones Share (%), by Country
  • Figure 12. Global Bioidentical Hormones share by Players 2023 (%)
  • Figure 13. Global Bioidentical Hormones share by Players (Top 3) 2023(%)
  • Figure 14. Global Bioidentical Hormones share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Biote Medical (United States) Revenue, Net Income and Gross profit
  • Figure 17. Biote Medical (United States) Revenue: by Geography 2023
  • Figure 18. Sottopell (United States) Revenue, Net Income and Gross profit
  • Figure 19. Sottopell (United States) Revenue: by Geography 2023
  • Figure 20. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 22. Full Life Wellness Center (United States) Revenue, Net Income and Gross profit
  • Figure 23. Full Life Wellness Center (United States) Revenue: by Geography 2023
  • Figure 24. Advantage Pharmaceuticals, inc (United States) Revenue, Net Income and Gross profit
  • Figure 25. Advantage Pharmaceuticals, inc (United States) Revenue: by Geography 2023
  • Figure 26. Pfizer Inc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer Inc (United States) Revenue: by Geography 2023
  • Figure 28. Defy medical (United States) Revenue, Net Income and Gross profit
  • Figure 29. Defy medical (United States) Revenue: by Geography 2023
  • Figure 30. GeneScience Pharmaceuticals Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 31. GeneScience Pharmaceuticals Co., Ltd (China) Revenue: by Geography 2023
  • Figure 32. Neuva aesthetics (United States) Revenue, Net Income and Gross profit
  • Figure 33. Neuva aesthetics (United States) Revenue: by Geography 2023
  • Figure 34. Global Bioidentical Hormones: by Type USD Million (2024-2029)
  • Figure 35. Global Bioidentical Hormones: by Product USD Million (2024-2029)
  • Figure 36. Global Bioidentical Hormones: by End User USD Million (2024-2029)
  • Figure 37. South America Bioidentical Hormones Share (%), by Country
  • Figure 38. Asia Pacific Bioidentical Hormones Share (%), by Country
  • Figure 39. Europe Bioidentical Hormones Share (%), by Country
  • Figure 40. MEA Bioidentical Hormones Share (%), by Country
  • Figure 41. North America Bioidentical Hormones Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Biote Medical (United States)
  • Sottopell (United States)
  • Novartis AG (Switzerland)
  • Full Life Wellness Center (United States)
  • Advantage Pharmaceuticals, inc (United States)
  • Pfizer Inc (United States)
  • Defy medical (United States)
  • GeneScience Pharmaceuticals Co., Ltd (China)
  • Neuva aesthetics (United States)
Additional players considered in the study are as follows:
Bioidentical Hormone Clinic (Australia) , Pharmac Biopharma (United Kingdom) , Biosyn Arzneimittel GmbH (Germany) , Bioidentical Hormone Clinic (Australia)
Select User Access Type

Key Highlights of Report


Jan 2024 224 Pages 67 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Bioidentical Hormones Market Quantitative research analysis
Global Bioidentical Hormones Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Bioidentical Hormones Market are by type [Estrogens, Progesterone, Testosterone and Others], by end use application [].
The Bioidentical Hormones Market is gaining popularity and expected to see strong valuation by 2029.
  • Rising Prevalence of Hormonal Imbalance Disorders
  • Increasing Focus on Women Health Care & Treatment of Hormonal among Women

Know More About Global Bioidentical Hormones Market Report?

Have a Query? Click Here

Other Related Reports

Clonorchis Infection Comprehensive Study by Therapy (Diagnosis (Microscopic Examination, Blood Test, Imaging Examination), Medication (Praziquantel, Albendazole)), Cause (Clonorchis Sinensis, Opistho...
$ 3450
Kidney Disease Comprehensive Study by Type (Chronic Kidney Disease, Acute Kidney Disease), Treatment (Dialysis, Medication, Kidney Transplantation), End-users (Dialysis Centers, Hospital & Clinics, R...
$ 3650
Clonorchiasis Comprehensive Study by Treatment (Praziquantel, Cystic, Biltricide, Others), Parasites (Clonorchis Sinensis, Opisthorchis Viverrini, Opisthorchis Felineus, Others), Diagnosis (Microscop...
$ 3450
Carpal Tunnel Syndrome Comprehensive Study by Drugs (Ibuprofen, Prednisone, Triamcinolone, Others), Treatment (Bracing or Splinting, NSAIDs, Surgical Procedure, Others), End-users (Hospitals, Clinics...
$ 3750
Chapare Hemorrhagic Fever Comprehensive Study by Therapy (Antiviral, Electrolytes, Others), End-users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online...
$ 3350
Cercarial Dermatitis Comprehensive Study by Mode of Administration (Topical, Oral, Injectable), Distribution Channel (Online, Offline (Hospital Pharmacies, Retail Pharmacies, Dermatology Clinics)), D...
$ 3650